Pulmonary vascular reactivity tests were performed in a young woman with mixed connective tissue disease and severe pulmonary hypertension. Vasoreactivity was documented in response to intravenous prostacyclin (PGI2), oral nifedipine, and inhaled nitric oxide, with quantitative differences. Nitric oxide produced a moderate lowering ofpulmonary arterial pressure and resistance without any deleterious systemic effect. The use of nitric oxide in testing for pulmonary vasoreactivity merits further evaluation. (Thorax 1995;50:96-97) 
Pulmonary hypertension in mixed connective tissue disease is often resistant to immunosuppressive agents.'2 Treatment with vasodilators might be the only option to improve survival, 3 and they have been shown to be effective in mixed connective tissue disease. 4 The prerequisite to initiating treatment is that vasoreactivity must be preserved. 3 (table) . PAP decreased within seconds of starting nitric oxide, while rebound followed its cessation ( figure) . A single bolus injection of cyclophosphamide (1000 mg), and methylprednisolone 250mg twice daily for three days, were administered. The patient was discharged on oral prednisone 60 mg/day and nifedipine, 20 mg three times daily.
Discussion
Vasoreactivity was present with all three vasodilators with quantitative differences. PGI2 produced larger decreases in PAPm and PVR than nifedipine (table). However, the baseline values were much lower for nifedipine than for PGI2.
The short half-life of PGI2 (1-2 minutes) should preclude any residual effect of the drug 24 hours later. However, we have recently documented major spontaneous variations in PVR (up to 32%) in patients with chronic pulmonary hypertension, during 72 hour measurements. 6 This could account for the differences observed in our patient. Nitric oxide decreased PVR by approximately 50% in patients with chronic pulmonary hypertension at an inspired concentration of 40ppm.7 Using the same concentration we observed a much smaller decrease (14%), but the baseline PVR in our patient was much lower. 7 The figure shows that, with all concentrations used, a transient drop in PAP occurred less than 30 seconds after the start of inhalation, followed by a rebound to baseline values and a slow decrease. This could be due to a reflex vasoconstriction compensating for the initial vasodilating effect of nitric oxide, but subsequently overridden by it. Furthermore, seconds after nitric oxide was discontinued a significant rebound was witnesseed. This could stem from pulmonary vascular hyperreactivity, as in systemic hypertension,' increased circulating catecholamines, or intracellular downregulation to the effects of nitric oxide. 9 No such overshoot occurred after PGI2 or nifedipine.
In conclusion, pulmonary vascular reactivity to nitric oxide in mixed connective tissue disease was documented without adverse systemic effects. Thus, even though only those vasodilators that also exhibit these side effects can be used for long term therapy at present, nitric oxide could represent a useful and safer test agent for vasoreactivity and should be studied further. The overshoot in PAP after discontinuation of nitric oxide merits a note of caution.
